Minervax ApS   Report issue

For profit Phase 1 Phase 2
Founded: Hellerup Denmark (2010)

Organization Overview

First Clinical Trial
2015
NCT02459262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Minervax ApS

Active Ingredients

Drugs in Phase 2 Trials (1)

gbs-nn/nn2 (4 trials)

Drugs in Phase 1 Trials (2)

aluminum hydroxide (Gaviscon) (1 trial)

gbs-nn vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Streptococcal Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3